FILTER

LATEST INTERVIEWS

Luis Azevedo

CEO, BRAVO MINING
"Carajás represents a frontier mining region where significant deposits are still viable, and we have already identified considerable mineralization, hinting at potentially groundbreaking discoveries."

Nathan Foster

MANAGING DIRECTOR KENNECOTT, RIO TINTO
"Over the next 24 months, we aim to make compelling investment decisions to extend mine life beyond 2032, particularly given the strong state of the copper market."

Joshua Olmsted

PRESIDENT AND COO AMERICAS, FREEPORT-MACMORAN
"We are always seeking near-term production increases through better efficiencies and productivity, but making a significant impact by 2027 will be tough for us and the industry."

Darrell White

GROUP EXECUTIVE AMERICAS, THIESS
"There is a renewed positive energy in Chile, and we are all optimistic about the future as these projects gain momentum."

Josée Méthot

PRESIDENT AND CEO, QUÉBEC MINING ASSOCIATION
"We anticipate a surge in new operations."

Mario Rouillier

PRESIDENT, GROUPE ROUILLIER
"During the spring we received visits from mining companies from Australia, Chile, and the USA, who are very interested in our autonomous drilling machines."

Luc Lessard

PRESIDENT, CEO AND DIRECTOR, FALCO RESOURCES
"Rouyn-Noranda is probably the best place in the world to build a mine."

Esteban Hormazábal

MANAGING DIRECTOR – CHILE, SRK CONSULTING CHILE
"Our clients are looking for advanced methodologies and technologies to address their challenges."

Rodrigo Morales

TECHNICAL DIRECTOR, TECPROMIN
"We won two large tenders with key lithium players in Chile to build significant projects."

Víctor Morales Baeza

VP EMEA MINING, ORICA
"Africa used to represent a small portion of our revenue, but over the past three years, we have nearly tripled our business here."

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

PARTNER EVENTS